Phase 2 N=3 A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Glioblastoma
Primary: Number of Participants With Change in Peritumoral Enhancement/Edema — 1; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=167 Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung · Lung Neoplasms
Primary: Objective Response Rate for Neratinib in Patients With Non-small Cell Lung Cancer — 3.3; 0; 3.6 percentage of participants
Phase 2 N=190 Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
Cystic Fibrosis
Primary: Safety as Determined by Adverse Events (AEs) — 30; 8; 7; 15 participants
N/A N=12 Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Chronic Myelomonocytic Leukemia-2 · Myelodysplastic Syndrome · Myeloproliferative Neoplasm
Primary: Overall Survival of Patients Over Age 60 With Newly Diagnosed AML/High Risk MDS — 7 participants
Phase 1 N=34 A Study of LY3009104(Baricitinib) for Healthy Subjects
Healthy Volunteer
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants
Phase 2 N=24 Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
Chronic Hepatitis D Infection
Primary: Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of Therapy — 0; 0; 0 Participants
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
Phase 3 N=133 A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Rheumatoid Arthritis
Primary: Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12 — 24.9; -16.6 units on a scale
Phase 3 N=5,285 A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)
Herpes Zoster
Primary: Incidence of Confirmed Herpes-Zoster — 6.737; 18.457 Number of cases per 1000 person years
Phase 4 N=27 Allopurinol Add-on Treatment for Refractory Mania
Bipolar Disorder · Mixed Mania · Treatment-Resistant Mania
Primary: Young Mania Rating Scale (YMRS) — -12.3; -9.6 units on a scale — p=.45
Phase 3 N=1,538 A Study in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 52 Week Endpoint in Hemoglobin A1c (HbA1c) — -1.55; -1.25 percentage of HbA1c
N/A N=133 Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
Xerosis Cutis
Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale
N/A N=222 Asthma Express: Bridging the Emergency to Primary Care in Underserved Children
Asthma
Primary: Symptom Days — 6.24; 4.82 symptom days over past 14 days — p=0.06
Phase 1 N=25 TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants
Healthy
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-020 — 104.182; 44.800; 139.522; 6.012 nanogram per milliliter (ng/mL) — p=<0.001
Phase 2 N=40 Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
Cystic Fibrosis
Primary: PC Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 5; 15; 13 Participants